A collaboration between a drug plan and clinical pharmacists led to nearly 50% of members successfully switching to a preferred dipeptidyl-peptidase-4 inhibitor.
Amy N. Thompson, PharmD
Advertisement
Articles by Amy N. Thompson, PharmD
Advertisement
Latest Updated Articles
Conditional Economic Incentives Could Be Effective in Improving Adherence to Long-Acting PrEP in Transgender AdultsPublished: August 18th 2025 | Updated: August 25th 2025
Semaglutide Not Associated With Increased Risk of Eye DisordersPublished: August 19th 2025 | Updated: August 22nd 2025
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?Published: June 6th 2025 | Updated: August 18th 2025
Report Reveals Mounting Burdens of Drug Shortages on US Health SystemPublished: June 27th 2025 | Updated: July 1st 2025
Managed Care Reflections: Insights From Richard J. Gilfillan, MD; and Donald M. Berwick, MD, MPPPublished: February 20th 2025 | Updated: February 21st 2025
FDA Proposal Aims to Reduce Smoking Addiction and SCLC CasesPublished: January 16th 2025 | Updated: January 29th 2025
Advertisement
Advertisement
Trending on AJMC
1
West Coast Health Alliance Releases First Vaccine Guidelines, Aiming to Replace CDC Recommendations
2
Hospitals in Underserved Communities Less Likely to Adopt Health Information Technology
3
Metabolic Issues More Common in Patients With HIV
4
Sotatercept Shows Right Heart Gains in PAH: Anjali Vaidya, MD
5
